MMC Principal, Charlotte Barttelot, leads our focus on data-driven health investments. In this episode, she interviews Patrick Short, founder and CEO of Sano Genetics - an MMC portfolio company that connects patients directly with biotech and pharmaceutical companies, accelerating research on rare and chronic diseases. The dramatic reduction of cost and time to sequence the human genome has led to the acceleration of personalised medicine. Charlotte and Patrick discuss the impact this has on the evolution of the drug development process, the change in attitude to the use of personal data, and how important the move towards greater trust and transparency in the industry is.